Ex vivo modifiable medicament release-sites final dosage form

摘要

Described embodiments include a final dosage form, an article of manufacture, and method. A described final dosage form includes a dosage portion having a medicament, and a site and the medicament in a first association. In the first association, the medicament has a first bioavailability. The first association of the site and the medicament is modifiable ex vivo to a second association an exposure to a stimulus, wherein the medicament has a second bioavailability. The final dosage form includes another dosage portion having another medicament, and another site and the another medicament in another first association. In the another first association, the another medicament has another first bioavailability. The another first association is modifiable ex vivo to another second association of the another site and the another medicament by an exposure to another stimulus, wherein the another medicament has another second bioavailability.